Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 9;23:69–79. doi: 10.1016/j.bioactmat.2022.09.027

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig. 3 — METTL14 combined with TLR4 agonist inhibit tumor and regulate macrophage polarization. (A) The cluster analysis of differentially expressed genes in pMETTL14 and normal groups of macrophages. (B) The GO enrichment analysis showed that METTL14 was remarkably correlated with the TLR4 signaling pathway of macrophages. (C, D) RS09 is one of the most common TLR4 agonists. The clone formation assay indicated that pMETTL14+RS09 group remarkably decreased tumor cell proliferation than other groups (**p < 0.01). (E) pMETTL14+RS09 significantly reduced the tumor volume when compared with other groups (**p < 0.01). (F) TLR4 showed a remarkably positive association with NOS2/iNOS (r = 0.222, p = 3.27e-04) of M1 type of macrophages via TIMER database. (G, H) The relative proportion of M1 (iNOS) and M2 macrophages (CD163) were observed in tumor tissues of control, pMETTL14, RS09, and pMETTL14+RS09 groups via IF staining (scale bar: 50 μm; **p < 0.01).